Amgen

Avsola

Manufacturer:

Amgen

Avsola HCPCS:

Q5121

HCPCS Code Descriptor:

Injection, infliximab-axxq, biosimilar, (avsola), 10 mg

Category:

Q Code

Avsola NDCs:

55513-0670-01

Primary Type:

Immunology Anti-TNF Biosimilar

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Avsola CPT Codes:

Potential CPT administration codes for Avsola can be found at the following link.

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Avsola:

Avsola is an Immunology Anti-TNF Biosimilar drug manufactured by Amgen and administered via the Intravenous route of administration. The Q Code: Q5121 is aligned to the drug Avsola.

Avsola works by binding to tumor necrosis factor alpha and preventing it from performing certain processes. Avsola is used to treat a variety of autoimmune disorders. This medication is manufactured by Amgen and is a biosimilar to the medication Remicade (J1745). Avsola was aligned to the HCPCS code Q5121 in July 2020. Patient assistance programs for this medication can be found through the Amgen Safety Net Foundation.

ACCESS PRICING AND MORE BY REGISTERING

Q5121 Added Date:

July 1, 2020

Q5121 Effective Date:

July 1, 2020

Q5121 Termination Date:

HCPCS Active

Avsola billing and coding information can be found through Amgen at the link below:
Avsola patient assistance information can be found through Amgen’s Amgen Safety Net Foundation at the URL: http://www.amgensafetynetfoundation.com
Avsola prescribing information can be found at the link below:
Information regarding Avsola’s side effects can be found at MedlinePlus